 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 1 | 1/1 | 返回列表 |
| 查看: 344 | 回復(fù): 0 | |||
狼行拂曉榮譽(yù)版主 (著名寫手)
~~~~
|
[交流]
DPP-4 Inhibitors for Type 2 Diabetes May Cause Severe Joint Pain
|
|
[DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain Audience: Patient, Endocrinology, Family Practice, Internal Medicine ISSUE: The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling. FDA has added a new Warning and Precaution about this risk to the labels of all medicines in this drug class, called dipeptidyl peptidase-4 (DPP-4) inhibitors. See the Drug Safety Communication for a complete list of all FDA-approved DPP-4 inhibitors. BACKGROUND: DPP-4 inhibitors are used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. When untreated, type 2 diabetes can lead to serious problems, including blindness, nerve and kidney damage, and heart disease. These medicines are available as single-ingredient products and in combination with other diabetes medicines such as metformin. RECOMMENDATION: Patients should not stop taking their DPP-4 inhibitor medicine, but should contact their health care professional right away if they experience severe and persistent joint pain. Health care professionals should consider DPP-4 inhibitors as a possible cause of severe joint pain and discontinue the drug if appropriate. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program: Complete and submit the report Online: www.fda.gov/MedWatch/report Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178. |
回復(fù)此樓» 猜你喜歡
高效肺靶向RNA轉(zhuǎn)染，加速肺部RNA藥物開發(fā)
已經(jīng)有2人回復(fù)
-
二糖的糖脂，合成后sephadex LH-20分離不出來，求助
已經(jīng)有1人回復(fù)
-
藥物學(xué)論文潤色/翻譯怎么收費(fèi)?
已經(jīng)有223人回復(fù)
-
南方醫(yī)科大學(xué)珠江醫(yī)院肖計(jì)生課題組招收博士生 （2026年入學(xué)）
已經(jīng)有2人回復(fù)
-
349藥學(xué)專碩105500求調(diào)劑
已經(jīng)有0人回復(fù)
-
求調(diào)劑
已經(jīng)有1人回復(fù)
-
298求調(diào)劑一志愿中海洋
已經(jīng)有3人回復(fù)
-
廣西醫(yī)科大學(xué)基礎(chǔ)醫(yī)學(xué)院自身免疫病課題組招收基礎(chǔ)醫(yī)學(xué)相關(guān)專業(yè)的調(diào)劑研究生
已經(jīng)有2人回復(fù)
-
藥學(xué)調(diào)劑申請(qǐng)自薦信，一志愿中南大學(xué)
已經(jīng)有1人回復(fù)
-
藥學(xué)349專碩求調(diào)劑
已經(jīng)有1人回復(fù)
-
《左乙拉西坦注射液制備工藝研究、質(zhì)量控制和穩(wěn)定性研究》下載
已經(jīng)有1人回復(fù)
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 狼行拂曉 的主題更新
| 1 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 281求調(diào)劑（0805） +6 | 煙汐憶海 2026-03-16 | 16/800 |
|
|---|---|---|---|---|
|
[考研] 一志愿吉林大學(xué)材料學(xué)碩321求調(diào)劑 +4 | Ymlll 2026-03-18 | 6/300 |
|
|
|
[考研] 一志愿985，本科211，0817化學(xué)工程與技術(shù)319求調(diào)劑 +7 | Liwangman 2026-03-15 | 7/350 |
|
|
|
[考研] 295求調(diào)劑 +3 | 一志愿京區(qū)211 2026-03-18 | 5/250 |
|
|
|
[教師之家] 焦慮 +8 | 水冰月月野兔 2026-03-13 | 12/600 |
|
|
|
[考研] 311求調(diào)劑 +6 | 26研0 2026-03-15 | 6/300 |
|
|
|
[考研] 304求調(diào)劑 +12 | 小熊joy 2026-03-14 | 13/650 |
|
|
|
[考研] 307求調(diào)劑 +3 | 冷笙123 2026-03-17 | 3/150 |
|
|
|
[考研] 26考研求調(diào)劑 +6 | 丶宏Sir 2026-03-13 | 6/300 |
|
|
|
[考研] 一志愿蘇州大學(xué)材料工程（085601）專碩有科研經(jīng)歷三項(xiàng)國獎(jiǎng)兩個(gè)實(shí)用型專利一項(xiàng)省級(jí)立項(xiàng) +6 | 大火山小火山 2026-03-16 | 8/400 |
|
|
|
[考研] 0703一志愿211 285分求調(diào)劑 +5 | ly3471z 2026-03-13 | 5/250 |
|
|
|
[考研] 085600材料與化工 求調(diào)劑 +13 | enenenhui 2026-03-13 | 14/700 |
|
|
|
[考研] 0856專碩279求調(diào)劑 +5 | 加油加油！? 2026-03-15 | 5/250 |
|
|
|
[考研] 一志愿哈工大材料324分求調(diào)劑 +5 | 閆旭東 2026-03-14 | 5/250 |
|
|
|
[考研] 材料與化工求調(diào)劑一志愿 985 總分 295 +8 | dream…… 2026-03-12 | 8/400 |
|
|
|
[考研] 311求調(diào)劑 +3 | 冬十三 2026-03-13 | 3/150 |
|
|
|
[考研] 求調(diào)劑 +5 | 一定有學(xué)上- 2026-03-12 | 5/250 |
|
|
|
[考研] 307求調(diào)劑 +5 | 超級(jí)伊昂大王 2026-03-12 | 5/250 |
|
|
|
[論文投稿]
投稿問題
 5+4
|
星光燦爛xt 2026-03-12 | 6/300 |
|
|
|
[考研] 333求調(diào)劑 +3 | 152697 2026-03-12 | 4/200 |
|